Ladies and Gents, I present to you the OMER play..... For those who missed the CRSR boat.
A heavily beaten down stock with a 800m market cap and a new FDA approved drug, the only kind in the market. Soon to be approved in the European market.
Already has a deal in place with Novo Nordisk valued at 2.1 billion.
With a low trading volume, a price target of $33 and a short float of 23%..... The only way is up!